KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Equity Average (2018 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Equity Average data on record, last reported at -$18.9 million in Q4 2025.

  • For Q4 2025, Equity Average rose 64.22% year-over-year to -$18.9 million; the TTM value through Dec 2025 reached -$18.9 million, up 64.22%, while the annual FY2025 figure was -$46.9 million, 43.7% up from the prior year.
  • Equity Average reached -$18.9 million in Q4 2025 per AQST's latest filing, up from -$38.3 million in the prior quarter.
  • Across five years, Equity Average topped out at -$18.9 million in Q4 2025 and bottomed at -$113.9 million in Q1 2023.
  • Average Equity Average over 5 years is -$72.3 million, with a median of -$69.0 million recorded in 2021.
  • Peak YoY movement for Equity Average: tumbled 272.14% in 2021, then soared 66.75% in 2024.
  • A 5-year view of Equity Average shows it stood at -$71.2 million in 2021, then tumbled by 58.88% to -$113.2 million in 2022, then increased by 7.49% to -$104.7 million in 2023, then skyrocketed by 49.59% to -$52.8 million in 2024, then surged by 64.22% to -$18.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were -$18.9 million in Q4 2025, -$38.3 million in Q3 2025, and -$66.8 million in Q2 2025.